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Abstract: The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial.
It is hypothesized that the critical events initiating this condition occur outside the brain, particularly
in the peripheral blood. Diagnoses of HIV-induced neurocognitive disorders largely rely on
neuropsychometric assessments, which are not precise. Total HIV DNA in the peripheral blood
mononuclear cells (PBMCs), quantified by PCR, correlate with disease progression, which is a
promising biomarker to predict HAND. Numerous PCR assays for HIV DNA in cell compartments
are prone to variation due to the lack of standardization and, therefore, their utility in predicting
HAND produced different outcomes. This review evaluates the clinical relevance of total HIV
DNA in circulating mononuclear cells using different published quantitative PCR (qPCR) protocols.
The rationale is to shed light on the most appropriate assays and sample types used to accurately
quantify HIV DNA load, which predicts severity of neurocognitive impairment. The role of monocytes
as a vehicle for trafficking HIV into the CNS makes it the most suitable sample for determining a
HAND associated reservoir. Studies have also shown significant associations between monocyte
HIV DNA levels with markers of neurodamage. However, qPCR assays using PBMCs are cheaper
and available commercially, thus could be beneficial in clinical settings. There is need, however,
to standardise DNA extraction, normalisation and limit of detection.
Keywords: HAND; HIV DNA; qPCR; biomarker
1. Introduction and Brief Pathology of HAND
Highly active antiretroviral therapy (HAART) has reduced the prevalence of AIDS related
opportunistic infections. Consequently, efforts are being directed at managing long-term HIV
complications such as central nervous system (CNS) diseases, which have continued to affect patients,
despite adequate virological control [1]. Some of the most frequent complications in patients with
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HIV-1 are HIV-associated neurocognitive disorders (HAND), which involve impairment or disruption
of neurocognitive functioning [2]. It is estimated that 20–69% of all HIV-1 cases have neurocognitive
disorders [3,4]. There is a wide range of disorders covered in the description of HAND according
to the 2007 Frascati criteria of categorising severity of neurocognitive impairment [5]. Dementia
associated with HIV, HAD, is the most severe form of HAND. Mild neurocognitive disorder (MND) is
characterised by minor neurocognitive impairment and asymptomatic neurocognitive impairment
(ANI) is characterised by two or more cognitive abilities with no functional impairment.
The precise mechanism of the neuropathogenesis of HAND is unknown, but studies have shown
that HAND is likely determined by a complex interaction between viral factors, cellular targets and the
immune response. Two models have been proposed to explain neurodegradation and the development
of symptomatic HAND; namely, the direct and indirect pathways (Figure 1). Both initially require
HIV-1 infection of the perivascular macrophages and microglia in the brain. According to the “Trojan
horse” hypothesis, HIV-infected perivascular monocytes/macrophages traffic HIV from the peripheral
blood to the CNS, leading to the infection of the resident microglial cells [6].
Viruses 2017, 9, 324  2 of 16 
 
despite adequate virological control [1]. Some of the most frequent complications in patients with 
HIV-1 are HIV-associated neurocognitive disorders (HAND), which involve impairment or 
disruption of neurocognitive functioning [2]. It is estimated that 20–69% of all HIV-1 cases have 
neurocognitive disorders [3,4]. There is a wide range of disorders covered in the description of 
HAND according to the 2007 Frascati criteria of categorising severity of neurocognitive impairment 
[5]. Dementia associated with HIV, HAD, is the most severe form of HAND. Mild neurocognitive 
disorder (MND) is characterised by minor neurocognitive impairment and asymptomatic 
neurocognitive impairment (ANI) is characterised by two or more cognitive abilities with no 
functional impairment. 
The precise mechanism of the neuropathogenesis of HAND is unknown, but studies have shown 
that HAND is likely determined by a complex interaction between viral factors, cellular targets and 
the immune response. Two models have been proposed to explain neurodegradation and the 
development of symptomatic HAND; namely, the direct and indirect pathways (Figure 1). Both 
initially require HIV-1 infection of the perivascular macrophages and microglia in the brain. 
According to the “Trojan horse” hypothesis, HIV-infected perivascular monocytes/macrophages 
traffic HIV from the peripheral blood to the CNS, leading to the infection of the resident microglial 
cells [6]. 
The direct pathway proposes that the viral proteins (Env gp120, Tat and Vpr), released from 
HIV-infected monocyte-derived cells, can cause neuronal death by direct interaction with neurons. 
Among the direct effects of viral proteins on neurons is neuronal depolarization by direct excitation 
independent of synaptic interactions, N-methyl-D-aspartate (NMDA) receptor dysregulation and 
disruption of calcium homeostasis in the case of Tat [7,8]. The indirect pathway suggests that 
neuronal death is mediated by inflammatory cells targeting HIV proteins released by infected cells. 
Infected or activated macrophages release a variety of soluble cytokines and chemokines, which are 
pro-inflammatory, including IL-6, GM TNF-α-CSF and IL-1β, which eventually leads to neuronal 
apoptosis [9,10].  
 
Figure 1. Mechanism of neuropathogenesis. Two pathways involved shown by arrows: (1) Direct 
pathway caused by HIV and released HIV proteins. (2) Indirect pathway involving secretion 
cytokines. (a) Virus particles and viral proteins shed and cross Blood brain barrier (BBB). (b) Neural 
injury caused by direct viral infection and dysregulation by viral proteins. (c) Infected monocyte 
infiltrating BBB. (d) Release of cytokines from infected monocytes contributing to disruption of BBB. 
(e) BBB become more permeable to cytokines present in the periphery. (f) More cytokines released 
into the brain and (g) cytokines disrupt normal functioning ultimately leading to neuronal apoptosis 
resulting in different forms of HIV associated neurocognitive disorders (HAND). 
Figure 1. Mechanism of neuropathogenesis. Two pathways involved shown by arrows: (1) Direct
pathway caused by HIV and released HIV proteins. (2) Indirect pathway involving secretion cytokines.
(a) Virus particles and viral proteins shed and cross Blood brain barrier (BBB). (b) Neural injury caused
by direct viral infection and dysregulation by viral proteins. (c) Infected monocyte infiltrating BBB.
(d) Release of cytokines from infected monocytes contributing to disruption of BBB. (e) BBB become
more permeable to cytokines present in the periphery. (f) More cytokines released into the brain and
(g) cytokines disrupt normal functioning ultimately leading to neuronal apoptosis resulting in different
forms of HIV associated neurocognitive disorders (HAND).
The direct pathway proposes that the viral proteins (Env gp120, Tat and Vpr), released from
HIV-infected monocyte-derived cells, can cause neuronal death by direct interaction with neurons.
Among the direct effects of viral proteins on neurons is neuronal depolarization by direct excitation
independent of synaptic interactions, N-methyl-D-aspartate (NMDA) receptor dysregulation and
disruption of calcium homeostasis in the case of Tat [7,8]. The indirect pathway suggests that
neuronal death is mediated by inflammatory cells targeting HIV proteins released by infected cells.
Infected or activated macrophages release a variety of soluble cytokines and chemokines, which are
pro-inflammatory, including IL-6, GM TNF-α-CSF and IL-1β, which eventually leads to neuronal
apoptosis [9,10].
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Since there is no standard protocol to assess the condition optimally, HAND is difficult to diagnose.
The screening and diagnosis for HAND relies on multiple clinical and neuro-psychometric methods,
such as the World Health Organisation (WHO) Auditory Verbal Learning Task (WHO-AVLT) and
the Revised Brief Visual Memory Task (BVMT-R) for learning efficiency [11,12]. These methods have
been used to define the scope and severity of HAND. However, there is need to compliment clinical
and neuropsychometric assessments with HIV-specific biological markers underlying symptomatic
HAND. The availability of reliable biomarkers would help to diagnose patients and bring a better
understanding of neuropathogenesis and therapeutic strategies to HAND [13]. Although many
proposed potential biomarkers for HAND have been described, there is a lack of sensitivity and some
of them are not HIV specific [14]. They include markers of monocyte activation such as soluble CD163
and CD14 (sCD163 and sCD14) [15], cytokine and chemokine receptors as well as markers of neural
injury and glial dysfunction [1,16–18]. They do not distinguish between the severity and HAND
subtype. No longer closely associated with neuropsychometric performance are HIV specific markers
such as plasma CD4+ T-cell count and viral load [19] in this era of HAART, where prevalence of HAND
in aviremic patients is common. Peripheral blood mononuclear cells (PBMCs) containing HIV DNA
has been linked to HAND progression in virally suppressed patients and therapy naïve patients [11,20].
This review summarises recent developments on the potential use of total peripheral blood mononuclear
cell-associated HIV DNA as a marker of HAND, focusing on PCR quantification assays. The rationale
is to highlight the potential clinical utility of this biomarker for HAND, considering the roles played
by different mononuclear cell compartments (lymphocytes compared to monocytes) or unfractionated
PBMCs in the proposed HAND pathogenesis models, bringing into context the suitability of different
samples used in different PCR assays. A careful analysis of published PCR methods regarding
sample type, sample loading quantity and quality, normalisation, robustness, accuracy, sensitivity
and specificity is required before total peripheral HIV DNA is used as a biomarker for HAND in
clinical settings.
2. Latency and Different Forms of HIV DNA in the Periphery
Immune cells are infected by HIV through CD4 receptors, and the co-receptors CCR5 and/or
CXCR4. The primary target cell is the CD4+ T lymphocyte. Following cellular infection, viral genetic
material (RNA) is then reverse transcribed into HIV DNA that becomes integrated into host DNA or
might exist as non-integrated linear and circular forms (1-LTR and 2-LTR circles) [21]. A subset
of these infected immune cells may become memory cells that harbour HIV DNA without the
production of virus (i.e., latently infected) [22,23]. This latency state may be disrupted if the cells
are re-stimulated/activated or when treatment is interrupted [21,23]. The HIV DNA is persistently
stored in a stable form in lineages of memory T lymphocytes and is protected from biochemical
decay [23]. Monocytes may be directly infected or may be infected following phagocytic uptake of
infected lymphocytes and/or free virions. Infection may occur in the blood or at the bone marrow
level [24]. Antiretroviral therapy (ART) reduces HIV RNA particles in circulating blood to undetectable
levels, but it cannot eliminate HIV DNA infecting white blood cells [22]. Latently infected cells are
disseminated throughout the body, but are differentially concentrated in the lymphoid tissues [25].
Blood is the most accessible tissue, but not the true representative medium for measuring the latent
reservoir [26]. Furthermore, the frequency of HIV infected cells is higher in the gut associated
lymphoid tissue than in the blood [27–29]. Outlined earlier, the systemic HIV DNA reservoir
trafficking to the CNS with activated cells (monocyte/macrophage lineages) causes activation-induced
neurodamage [30,31].
The easy accessibility of peripheral blood as a clinical specimen makes it more feasible to
investigate the contribution of peripheral HIV DNA reservoirs to pathogenesis of neurocognitive
impairment [24,28]. Peripheral HIV DNA is an independent predictor of HIV disease irrespective of
combined antiretroviral therapy and was widely used in both adult and paediatric cohorts [32–35].
The HIV DNA in peripheral blood has also been used as a prognostic marker of disease progression,
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especially in suppressed patients where it is the only biomarker of viral activity [35]. Therefore,
it is possible to investigate the role of peripheral HIV DNA in neuropathogenesis by evaluating the
association between the clinical categories of HAND (ANI, MND and HAD) and the quantities of HIV
DNA. Available assays can quantify both total and unintegrated HIV DNA forms (linear, 1-LTR and
2-LTR) [36,37].
3. What Samples Can Be Used to Measure HIV DNA as a Biomarker for HAND?
Assays to quantify HIV DNA by qPCR have utilised both PBMCs and sorted cell subsets as
clinical samples, but choices must be made on the most appropriate samples to collect and process [38].
The appropriate clinical specimen in HIV DNA qPCR should give a true size on the peripheral
HIV-1 DNA pool and its composition [36], which enables clinical diagnosis and monitoring disease
progression [39,40]. It is important to decide on the type of sample and form of DNA to use as a
marker to define and monitor the progression of HAND, considering the size of the HIV reservoir
in the sample and its role in the pathology of the disease. An appropriate clinical specimen gives
information which reflects on the condition of the disease by correlating with findings from clinical
assessments [41]. The choice of the sample should consider the stage of HIV disease as it is known that
there are differences between early HIV disease and advanced stages of infection with regard to shift in
tropism [42]. Advanced stages of HIV diseases shows depletion of CD4+ T lymphocytes, while there is
both expansion and increased turnover of peripheral monocytes, including CD14+/CD16+ subsets
known to be associated with increased susceptibility to HIV infection [43]. Therefore, investigations
should consider the clinical stage of neurocognitive impairment/severity of HAND since there is likely
to be differences in quantities of PBMC subsets and the composition of different forms of HIV DNA
in the cells. Sample type is very critical because it has implications, first on the quantity and forms
of DNA in the cell type and, second, the role played by the cell type in HAND pathogenesis. All
three forms of HIV DNA have been detected in brain tissues of patients having AIDS dementia [44].
Some studies have measured HIV DNA quantities using the whole blood, while others have used
PBMC and found good correlation between the two samples [34,36]. To consider peripheral HIV DNA
load as a reliable virological marker of HAND in clinical settings, a careful assessment of PBMC and
its cell subsets as appropriate samples is required.
3.1. Unfractionated PBMC
Peripheral blood mononuclear cells constitute the cellular part of the blood containing cells with
a round nucleus, namely monocytes, T cells, B cells, Natural killer cells (NK) and dendritic cells [45].
Peripheral blood mononuclear cells (PBMCs) are involved in many immune-related diseases and there
is growing interest to use them as surrogate markers of several diseases [46,47]. These PBMCs can be
obtained relatively easily from routinely collected blood samples without analytical difficulties [48].
Thus, there is a growing interest to use PBMCs diagnostically as surrogates for direct sampling of
sites of infection and to investigate other disease processes such as HIV-associated neurocognitive
impairment [32,49]. It has been demonstrated that HIV DNA levels in PBMCs correlate with antiretroviral
therapy efficacy, suggesting that DNA quantitation is a useful tool to monitor the decay of the HIV
reservoir, especially when plasma viremia is undetectable [50].
Significant positive correlations between levels of HIV DNA measured in PBMC and CSF cell
pellets has been reported in HAND patients, showing that there was a link between peripheral
blood HIV reservoirs which influence CNS HIV DNA quantities [51]. Measurement of HIV DNA in
unfractionated PBMCs using PCR is the simplest way of quantifying the reservoir in the peripheral
blood [52]. The PBMC HIV DNA levels have been linked to cortical and subcortical grey matter atrophy
in patients on HAART with undetectable viral load, and it was also observed that HIV DNA in PBMCs
in HAD was 20 times higher than in uninfected individuals [53,54]. Since brain biopsy and CSF are
not a clinically feasible option in HAND studies, utility of PBMCs is imperative. The quantity of HIV
DNA in unfractionated PBMCs represents the true size of the peripheral HIV reservoir, in fact, because
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HIV DNA differentially distributed in all cell subsets are considered in PCR assays [31]. However,
some studies on the association between HIV DNA in unfractionated PBMC and HAND did not
show significant correlation [53]. Therefore, there is need to analyse the role of separate peripheral
mononuclear cell subsets (Lymphocytes/monocytes) in neuropathogenesis.
3.2. Lymphocytes
The primary target for HIV infection in the peripheral blood are CD4 T lymphocytes, which makes
them the predominant cell type harbouring HIV-1 in the peripheral blood of infected individuals [55–57].
The majority of HIV DNA is contained within memory (CD57−CD4+) T cells [57]. Research has also
found that all forms of HIV DNA persist in resting CD4 cells, suggesting that there is replenishment of
the reservoir, either by reactivation or by infection [21,57]. It has also been demonstrated, both in vitro
and in vivo using animal models, that cytotoxic T lymphocytes can be infected by HIV-1 (Stanley et al.,
1993). It is thought that the infection takes place during the peripheral interaction between CD4
and CD8 as part of an immune response, thereby allowing direct transmission of HIV-1 to the CD8
lymphocytes [27,56]. Using CD4 and CD8 naive and memory cell populations separated from PBMCs
of HIV-seropositive individuals, frequencies of infected cells ranged from 30 to 670 proviral copies/106
CD4+ lymphocytes and from 8 to 500/106 CD8 lymphocytes [56]. The reservoir of HIV in CD4+ and
CD8 lymphocytes is of clinical significance due to their important role in HIV pathogenesis, as well
as their routine application in diagnostic settings as markers of HIV infection. Using qPCR targeting
the HIV gag region, it was shown that memory CD57−CD4+ T cells were always more frequently
infected (10–10,000 copies of gag DNA/105 cells) than effector CD57+CD4+ T cells [58]. The quantity
of infected memory cells in this study also correlated with plasma viral load, which is a virological
marker for monitoring and predicting HIV infection. However, with regard to HAND, there are
limited data on correlation studies linking peripheral lymphocyte HIV DNA levels and severity of
neurocognitive impairment [42,51]. Investigations using ART naïve participants with mild to moderate
neurocognitive impairment, lymphocyte HIV DNA levels were shown to be significantly associated
with HAND independent of plasma viral load and CD4+ count [42,54]. There is need for more data
on association studies between peripheral lymphocyte HIV DNA reservoirs and HAND, since this is
the preferential target of HIV infection [57]. Activated CD4+ T lymphocytes support viral replication
and resting cells support establishment of a latent reservoir [58,59]. The result of HIV replication in
activated lymphocytes is the production of different forms of HIV DNA (linear, 1-LTR and 2-LTR) and
resting cells predominantly constitute integrated HIV DNA, both of which have shown to have clinical
consequences in the brain HAND patients [60,61]. Therefore, this cell subset can represent the true
size of the reservoir with different forms of HIV DNA.
3.3. Monocytes
There are two major types of monocytes in the blood, classical monocytes that have a high
expression of CD14+ cell surface receptor (CD14++ monocytes) and non-classical, pro-inflammatory
monocytes with a low CD14+ marker, but with an additional CD16+ marker (CD14+CD16+
monocytes) [62]. However, it has been reported that there is heterogeneity in CD14+CD16+ monocytes
which resulted in subdivision of the pro-inflammatory monocytes into intermediate (CD14++CD16+)
and non-classical (CD14+CD16++) monocytes [63]. Analysis by cellular subsets revealed that
differences in cognitive categories are related to the amount of HIV DNA within inflammatory
monocytes (CD14+CD16+) as compared to non-inflammatory monocytes (CD14+CD16−) or the
CD14− fraction, which includes the lymphocytes [53,64]. Using a series of immunohistochemical
markers, studies have demonstrated that CD14+CD16+ monocytes derived from the periphery
accumulated in the perivascular region of the brain in patients with dementia [65]. The infection of
monocytes by HIV is thought to arise from virus released from re-activated infected CD4+ T cells in
the blood or infection at the bone marrow level [27,62,66].
Viruses 2017, 9, 324 6 of 17
The CD14+CD16+ monocyte subset in the peripheral blood constitutes only 5–10% of peripheral
blood monocytes in healthy individuals, but the percentage increases to approximately 40% in HIV
infected people [67]. Both in vitro and in vivo studies demonstrated that CD14+CD16+ monocytes
express high amounts of the co-receptor CCR5, which facilitates their infection. It has also been
observed that cells of the monocyte lineage are not susceptible to the cytopathic effects of HIV and,
once they are infected in the periphery, they produce infectious virions as they enter the CNS and when
they differentiate into macrophages [27]. Monocytes circulate in the blood for up to three days before
they enter tissues [27,62,66,67]. Since monocytes are only present for 1–3 days in the blood, the presence
of viral DNA within these cells indicate recent infection [68]. Monocytes isolated from blood of HIV
patients were shown to contain unintegrated circular viral DNA, suggesting transcriptionally active
rather than latent infection [69]. However, it has been shown that blood purified monocytes contain
HIV DNA over time in both treated and untreated patients [7,27,70,71].
Monocytes circulate freely and patrol blood vessels as they respond to inflammation signals
in tissues, such as exposure to viral products such as gp120, which can trigger chemokine
production [72]. Upregulation of chemokines lead to movement of monocytes into various tissues
and this process is thought to drive trafficking of monocytes through the blood–brain barrier. Studies
also observed higher levels of HIV-1 DNA in activated inflammatory monocytes (CD14+/CD16+)
than in non-activated monocytes [73]. Accumulating evidence shows that the route of CNS
infection appears to involve circulating activated monocytes (CAM) [73]. Increase in peripheral
activated monocyte subsets correlates with HIV disease progression and severity of neurocognitive
impairment [62,74]. Research has demonstrated that individuals with HAD had higher levels of
circulating activated CD14 monocytes and monocytes that co-express CD69, as compared to those
without HAD. The finding supports the hypothesis that activated monocytes enter the brain and
subsequently trigger neurotoxin production [75]. Individuals with HAD have a higher percentage of
circulating activated monocytes/macrophages (M/MΦ), suggesting that HIV-1 DNA harboured in
these reservoir cells is transported into the CNS by the same cells [73,76]. This evidence supports that
accumulation of activated macrophages/microglia resulting from systemic immune activation trigger
neurodegeneration in HAND [72,77]. It is clinically not feasible to sample brain tissue to determine
macrophage/microglial viral DNA levels in clinical studies and routine diagnostics. Therefore, blood
is the best option. Investigations using some animal models have shown that infected monocyte
transmigration into the CNS appear to trigger gene expression of quiescent cells [61]. This finding raises
the possibility that latent HIV harboured in peripheral monocytes may have clinical consequences
upon BBB transmigration [60]. Viral DNA in blood monocytes in one study was significantly associated
with eight of the nine cognitive domains that are frequently impaired in HAND [78,79]. Using magnetic
resonance spectroscopy, it was demonstrated that neuronal injury and glial dysfunction was positively
linked to peripheral CD14+ HIV DNA [80,81].
4. Quantitative PCR Assays to Detect Total HIV-1 DNA
There are a number of real-time PCR based assays to measure total HIV-1 DNA or cell associated
DNA. These assays differ in extraction methods, PCR cycling conditions and amplification targets [82].
Some assays lack the sensitivity to quantify all the HIV-1 subtypes in the major (M) group, due to
the high degree of genetic variability of the virus [83]. The genetic differences may result in DNA
copy number variations due to probe and primer mismatches. The differences in PCR-based protocols
for quantifying cell-associated HIV DNA has made it difficult to compare studies. Some of the
confounding factors that result in non-specific variation in proviral load include input template
quantity and quality, yields of the extraction process and enzymatic reactions [84]. Therefore, it is
very important to prescribe the minimum requirements for a PCR-based assay to determine HIV
proviral load. A requirement for quality PCR is that the extraction method produce high purity
DNA that is free from haemoglobin, alcohol or high salt concentrations that may interfere with PCR
amplification. Another critical requirement for determining HIV DNA proviral load in clinical samples
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is the assessment of the number of human cells per sample before DNA extraction [85]. The number
of cells determined by flow cytometry is used to normalise HIV DNA in a sample [86]. Normalisers
are used to ensure that target quantities from an equivalent amount of samples are comparable in
absolute quantification, [73,87]. Data normalisation, which can be done by including an endogenous
gene (reference gene) in the assay, is one of the essential key elements on the Minimum Information
for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines [88].
Normalisation is done to reduce non-biological variation as much as possible so that a
true biological variation, explaining the phenomenon under investigation, is determined [84,89].
Housekeeping genes, such as Glyceraldehyde phosphate (GAPDH), β-globin, β-actin and Telomerase
Reverse Transcriptase (TERT), determined by qPCR, were used for normalisation of HIV DNA to cell
equivalents in some studies [28,31,73,90]. These PCR methods are more accurate than cell counts from
cell sorting. The normaliser can also be used for quality control purposes since the numbers of cell
inputted affect the sensitivity, as well indicating the presence of PCR inhibitors that might alter the
sensitivity of the assay [91].
Malnati et al. in 2008, developed a universal HIV-1 group M-specific qPCR with a similar
degree of accuracy and sensitivity across all viral subtypes. The designed primers and probe allow
correct quantification of virtually all circulating HIV-1 strains. The universal assay amplifies part
of the LTR-gag region that is highly conserved among all circulating group M HIV-1 subtypes [92].
The success of this group M-specific HIV-1 qPCR is based on the optimised design of primers and
probes that ensure quantification of all the strains in the group. To obtain a standard for construction
of a calibration curve, a fragment containing the conserved LTR-gag region was amplified from the
T lymhoblastoid cell line using the optimised primers as described by Malnati. The fragment was
then cloned into pCRII plasmid, from which serial dilutions were made to make standard curves.
An additional qPCR was developed, in this assay, to measure the number of human cells initially
present in a sample and to normalise the HIV-1 proviral DNA. This was done by measuring the copy
number of a single copy human gene CCR5. The CCR5 assay permits the assessment of the sample
quality as well as the number of cells. This protocol performs well if the input sample contains between
1000 and 150,000 cells per reaction. This robust method can quantify HIV-1 DNA from a crude lysate
with the same degree of accuracy as with purified DNA. The advantage of a crude lysate is that it
circumvents the nucleic acid extraction process, makes the assay take a shorter time and reduces the
costs of the assay. The assay becomes suitable for large clinical trial cohorts.
Using cell lysate, Vandergeeten et al. [91] developed a nested real-time to measure total HIV DNA
from diverse subtypes. The first round of PCR was pre-quantification duplex PCR with two sets of
primers, one for the HIV-1 and the second set for the normaliser CD3 gene. The second round PCR was
real qPCR performed separately for HIV quantification and for determination of cell input using the
CD3 gene. The primers and probes for this assay, which target the conserved LTR-gag region, allows
the precise quantification of total HIV DNA from subtypes, A, B, C, D, CRF01 A/E and CRF02_A/G,
with the detection limit of three copies for all subtypes. The assay also showed that HIV DNA copies
were detected with similar efficacy if the cell input ranges from 10,000 to 300,000. The assay clearly
demonstrated the cell input sensitivity of HIV DNA quantification.
Recently, a simple and reproducible qPCR assay for cell-associated HIV-1 DNA was developed
targeting the conserved 3’ part of the integrase region of the pol gene with a sensitivity of three to five
copies per million cells [82]. The 3’ end of the HIV-1 pol gene has been shown to be the most highly
conserved region, meaning that primers and probes targeting this region should amplify efficiently the
largest numbers of samples from HIV-1 infected people without mismatches. The sensitivity of this
assay was determined by testing the limiting dilution of DNA standards in accordance with the Poisson
distribution. The assay was able to detect three copies of HIV DNA standards in 80–100% of the reactions.
Low detection limit (LOD) of three genome copies shows that the assay is very sensitive. Inhibition of HIV
DNA PCR by excess nucleic acid was prevented by the dilution of the extract to≤170 ng/µL. The nucleic
acid extract was also diluted by 1:30 for CCR5 qPCR. The control of the nucleic acid input for both HIV
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DNA and the CCR5 normaliser is important to avoid underestimation of proviral load through inhibition.
Many other PCR based assays are used in monitoring the HIV reservoir in clinical trials and HAND studies,
but they differ in many ways including target region, normaliser, sample type, sample input quantity,
standards, limit of detection and cycling conditions [26,31,82]. Table 1 shows selected methods used in
qPCR for HIV DNA showing different parameters, including the ANRS commercial assay, which has
been evaluated for inter-laboratory reproducibility.
Table 1. Selected technologies used in quantitative HIV DNA real time PCR assays.
Assay Normalisation Unique Features andAdvantages/Disadvantages
PCR Template
Loading Quantity LOD Reference
Whole blood
ANRS LTR real
time PCR
Method
HIV-DNA copies/µg
converted to
copies/million
leucocytes
HIV DNA extracted from re-suspended
whole blood cell pellets
No separation of cells
Its quicker and cost serving
Normalisation using cell
count/cytometry is not accurate
1 µg DNA,
equivalent to
150,000 cells
1 Copy [34]
LTR ANRS LTR
real time PCR
Method
Copies/million/PBMC
First assay for estimating HIV reservoir
size to be evaluated for inter-laboratory
reproducibility. The assay available as a
commercial
1 µg DNA,
equivalent to
150,000 cells
1 Copy [34]
SYBR Green
gag HIV DNA
PCR
Copies/hundred
thousand cells
Uses SYBR green fluorescence and
amplifies a 142-gag fragment
The assay is not sensitive especially in
suppressed patients
300 ng, equivalent
to 1,000,000 cells 50 Copies [27]
Cross-Clade
Ultrasensitive
nested PCR
CD3 gene copy cell
equivalents
Assay is performed on cell lysate, hence
circumvents laborious nucleic acid
extraction
Allows quantification of HIV DNA A, B,
C, D, CRF01_A/E, and CRF02_A/G
HIV-1 subtypes, targeting highly
conserved LTR-gag region.
Cell input equivalence is accurately
quantified by CD3 gene quantitative PCR.
It has a disadvantage of 2 rounds of PCR
100,000 Cells 3 Copies [91]
universal
real-time PCR
for group-M
HIV-1 DNA
CCR5 gene copy cell
equivalence
HIV-1 M-specific quantitative measures
the HIV-1
Proviral DNA load in group M with a
similar degree of sensitivity and accuracy
across subtypes.
Uses cell lysate as a template
Predilution required if loading quantity is
above 150,000 cells
1 µg per reaction,
equivalent to
150,000 cells
1 Copy [92]
Novel Assay
for Total cell
associated
HIV-1 DNA
CCR5 gene copy cell
equivalence
Sensitive Quantitative real time PCR for
HIV-1 Cell associated DNA (CAD)
targeting 3’ region of the pol gene.
Assay involves enhanced nucleic
extraction by ensuring adequate cell lysis
through ultrasonic cell disruption
1.7 µg 3 Copies [82]
5. Relevance of Total HIV DNA qPCR Assays to HAND
Many studies have evaluated and demonstrated the prognostic value of total HIV DNA
measurement by qPCR as a marker of disease progression, independent of plasma viral load and CD4+
count [27,36,93,94]. High levels of HIV DNA were associated with rapid progression to AIDS and
death in treatment naïve patients [41]. A suitable HIV DNA qPCR assay for HAND should target a
clinically relevant marker and should be highly specific, sensitive, reproducible, cost-effective and easy
to implement in clinical settings. Both replication-competent and defective forms of HIV DNA have
been shown to be clinically relevant to neurocognitive impairment [44,60,61]. It is well understood
that the different forms of HIV DNA co-exist in an infected cell, although their distribution varies
depending on whether the cells are activated or latent [36,57,93,95]. Therefore, it is important to
quantify all forms of HIV DNA, including the defective and unintegrated forms, and utilise them as
surrogate biomarkers for HAND pathogenesis. It is also cost effective to have a qPCR that quantifies
all the different forms of HIV DNA rather than separately quantifying integrated forms, 1-LTR or
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2-LTR. Total HIV DNA qPCR assays can be applied to whole blood, PBMCs, monocytes or lymphocyte
subsets and is easy to measure [31,34,42,96]. The assay quantifies all forms of HIV DNA that co-exist in
infected cells that are involved in HIV pathogenesis [31,57]. Comparing measures such as 2LTR circles
or integrated HIV DNA, total HIV DNA has the advantage of easy quantification, by standardised
sensitive, real-time PCR methods [34]. It is suitable for analysing large samples with accuracy, requires
a relatively small amount of blood and is not affected by freezing–thawing [96]. However, there is no
commercial assay currently available for HIV DNA qPCR [41]. The above-described assays, including
the ones that have been used on HAND studies, are a modification of commercial assays used in HIV
RNA quantification [82,97]. Thus, an assessment of qPCR applied in HAND studies is required with
regard to sensitivity and the sample types that were used in the assays.
6. HIV-1 DNA qPCR Used in HAND Studies
Application of qPCR and digital PCR to determine the association between HIV DNA levels in
PBMC and its fractions, in the context of HAND, needs to consider both clinical and demographic
variables of the study cohorts as well as the severity of HAND and performance characteristics
of the assays. Using a very sensitive qPCR assay (LOD of 1–3 copies), it has been demonstrated
that HIV DNA correlated with HAD in both HAART-naïve and HAART treated patients [73,80,81].
These studies also showed that activated monocytes HIV DNA levels in HAD patients were higher than
in lymphocytes including the CD4+ cells. The sensitivity of the assay allows detection of low copies
in suppressed patients and those who commence ART early in the course of HIV infection. Using a
full range of neurocognitive disorders, the assay also showed that people with normal cognition had
lower peripheral HIV DNA levels as compared to those with minor motor disorders and HAD [80].
Results of this study showed that the assay was sensitive enough to determine the association between
circulating HIV DNA and different stages of HAND from normal cognition to the extreme forms
of HAD. The HIV DNA determined by this assay, as a proposed biomarker, has been shown to be
proportional to all three levels of neurocognitive function as well as different neuropsychological
deficits, making it applicable for both screening and monitoring therapeutic interventions.
The HIV DNA assay targeting the gag region has shown that monocyte HIV DNA levels
correlated with all three clinical categories of HAND (ANI, MND and HAD) in HAART treatment
naïve patients [11]. The study further demonstrated association between monocyte HIV DNA and
glial dysfunction, neuronal injury and CSF immune activation. The important aspect of this study
demonstrates the link between both neurobehavioral and neuropathological aspects of HAND and
circulating HIV DNA levels. However, there was no association between PBMC HIV DNA and HAND.
Different HIV DNA PCR assays including droplet digital PCR used on HAND studies produced
different results depending on clinical and demographic characteristics of study participants, as well
as performance characteristics of the assays [42,51,80]. Table 2 shows selected PCR assays used in
HAND studies with clinical data for study participants and performance characteristics of the assays.
Table 2. HIV DNA real time PCR assays applied in HAND studies.
Reference Target Sample Clinical Data Study Outcome Advantage/Disadvantage
[73] gag PBMC
HAD patients on
HAART
20–39 years and
50 years and above
Quantities of HIV DNA
correlated with HAD
HIV was higher in activated
monocytes than CD14− in
two patients
Very sensitive Quantitect Sybr
Green PCR assay with
detection limit of 1–3 copies
and applicable suppressed
patients and those with low
cell PBMC or cell subset
counts
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Reference Target Sample Clinical Data Study Outcome Advantage/Disadvantage
[78] gag
PBMC,
CD14+,
CD14−
15 HAART-naïve
HAD patients and 15
Non demented
patients
Average age, 34.1
HIV DNA in PBMC was
significantly higher in HAD
non demented patients
HIV DNA in five HAD
patients was higher in
CD14/CD16 than CD4
Very sensitive Quantitect Sybr
Green PCR assay with
detection limit of 1–3 copies
and can be applied to
suppressed patients and
samples with low cell count
[31] pol PBMC
HIV Subtype B
chronic patients on
cART for six months
CD4+ < 350/mL
Median Age 56, 74
HIV DNA was associated
with HAD and not
Non demented forms of
HAND
Very sensitive assay with one
copy as LOD, hence suitable
for supressed HAND patients
PCR has a wide dynamic
range from three copies to
300,000 copies
High efficiencies for both
HIV DNA and β-actin
normaliser
(93.7% and 86.6% respectively)
-Assay restricted to detecting
Subtype B
[42] LTR-gag
CD14−
and
CD14+
ART naïve
participants (median
age, 32) with
17 impaired and
19 unimpaired
Patients had higher
HIV DNA in
lymphocytes than
monocytes
Strong association between
HIV DNA levels in
lymphocytes and HAND
The target region for
amplification is highly
conserved and the Universal
PCR assay has been
customised for subtype G and
CRF02_AG.
However, performance of the
assays not detailed
[79] gag CD14+
12 HAART treated
HAD and 15 non
HAD Infected with
HIV-1 CRF01_AE
Median Age, 32
Baseline monocyte HIV DNA
correlated with HIV DNA and
48 weeks after HAART.
Monocyte HIV DNA level was
below detection limit in all
non-HAD patients after 48
weeks
Detection limit of the assay
was 10 copies/106 cells which
is relatively high.
[11] gag CD14+PBMC
Treatment naïve with
three clinical
categories of HAND
(ANI, MND, HAD)
CD4+ <350/mL
–CRF AE_01Mean
Age, 35
No correlation between PBMC
HIV DNA
Before CD14+ enrichment,
CD14+ was associated with
HAND(ANI, MND, HAD)
–CD14+ HIV DNA was
associated with glial
dysfunction, neuronal injury
and CSF immune activation
(neopterin)
Very sensitive assay with a
limit of detection of one copy
which is suitable for HAND
suppressed patients
[51] pol PBMC
22–40 years and
50–71 years
ART-supressed HIV
subjects
Higher HIV DNA levels were
associated with more severe
neurocognitive impairment in
older patients
No association between HIV
DNA and HAND in young
adults.
Very sensitive droplet digital
PCR with Limit of Detection
(LOD) of one copy and more
precise than qPCR due
insensitivity to primer and
probe mismatches
absolute quantification, no
external standards required
7. Possible Use of Digital PCR to Detect HIV DNA in HAND
The amplification signal is logarithmic and the quantification is based on an external calibration
or standard curve in the above described qPCR methods. A relatively newer technology called
digital PCR (dPCR) offers simple, linear and digital quantification that is based on the number of
positive and negative reactions using Poisson distribution [98]. Digital PCR uses limiting dilutions
and sample partitioning into submicrolitre reactions. Each partition represents an isolated end point
PCR [99]. The Poisson distribution of template molecule within these partitions is used to deduce the
concentration of the target nucleic acid from frequency of negative to partitions. Digital PCR has been
shown to be tolerant with sequence variations by higher robustness to primers and probe mismatches
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with target sequences, giving a superior advantage for HIV-1 DNA quantification and, as a result,
dPCR has shown higher accuracy precision and reproducibility over qPCR.
Regarding detection and quantification of HIV proviral DNA in HAART suppressed patients,
which are usually very low but relevant to HAND, dPCR can offer an alternative to qPCR based
assays [51]. Most patients who are on long term ART, the proviral load ranges from 10 to 1000 copies
of HIV DNA per million cells [25,99]. The higher sensitivity of dPCR compared to qPCR will be more
relevant to the determination of low quantities of HIV DNA in monocytes in the periphery, which have
been shown to be predictive of HAND and thought to be a major source of virus production in
the brain [67]. Although dPCR has a great potential to be used as a valid alternative to qPCR,
there is need to eliminate false positive droplets, which have been reported in negative template
controls [100]. The other hurdle in the utility of dPCR for precise measurement of HIV DNA is the lack
of a standardised automated method for determining threshold droplets. Threshold setting is very
important to determine baseline fluorescence in order to distinguish between positive and negative
droplet populations without bias [101]. There is also a need to work on the reduction of cost so that
dPCR can be clinically accredited.
8. Conclusions
Classical virological and immunological parameters such as plasma viral load and CD4+ T-cell
counts for HIV normally used to monitor the progression of disease cannot be used to measure and
predict the onset of HAND. Most of the proposed markers of HAND are similar to the biomarkers of
other neurocognitive disorders due to the similarities in the molecular mechanisms that are involved.
The HIV DNA or cell-associated DNA (CAD) is detected in the peripheral blood of HAART suppressed
patients and many studies have shown it to correlate with HAND. However, there is a need for an
assay that is robust, sensitive and accurately quantifies HIV DNA. Total HIV DNA quantification
by real-time PCR from unfractionated PBMCs is very simple, but HIV DNA from inflammatory
CD16+ monocytes is linked to the pathogenesis of HAND and, therefore, more suitable as a marker.
Regarding quantification of low level HIV DNA in HAART suppressed patients, dPCR offers a superior
advantage, but issues to do with standardization of threshold and cost reduction need improvement
before utilisation in diagnostic settings. Therefore, qPCR methods remain relevant now for clinical
use since research has shown significant association between peripheral HIV DNA levels in cell
compartments and severity of HAND. Additionally, evaluated commercial qPCR kits for HIV DNA
load are now available. However, more data are required on T cell HIV DNA as an indicator of
potential HAND-associated reservoirs in untreated patients.
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